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ABSTRACT 
 
 After the development of the viral-based prostate cancer vaccine, Ad5-
PSA, much research has been orientated to help enhance the induced immune 
response by combining the vaccine with physical and chemical modulating 
agents, more specifically the polymers polyethylenimine (PEI), chitosan, and 
chitosan coated with CD3 complex antibodies; all previously shown to stimulate 
an immune response as isolated gene carriers.  To compare the vaccine-induced 
immune responses between the naked vaccine and the polymer-vaccine 
combinations, a mouse model using the ovalbumin- specific Ad-OVA vaccine 
was tested using intracellular cytokine staining (ICS), tetramer staining, and 
cytotoxic T-cell lymphocyte assays to measure the activation of CD8+ T-cells, 
interferon gamma proteins (INFγ), and the induced cytotoxicity to ovalbumin.  The 
Ad-OVA vaccine combined with both chitosan and chitosan with CD3 complex 
antibodies, both natural polymers, were found to induce similar immune 
responses to the naked vaccine while the vaccine combined with the synthetic 
polymer, PEI, diminished the immune response.   
 
INTRODUCTION 
 History of Cancer.  Although not yet identified as the epidemic we know 
today, ancient fossil and mummies pre-date the existence of cancer to ancient 
Egypt in approximately 1600 B.C.  It was not until 400 B.C. that the “Father of 
Medicine” Hippocrates coined the term cancer, referring to the crab-like 
extensions from the disease.  Labeled as “incurable” in ancient manuscripts, the 
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doctors of the Renaissance were the first to suggest that surgery may be 
effective if the tumor was “movable.”  The development of pathology of the 19th 
century first allowed causes of death to be associated with the pathologic state of 
the corpse, opening the door for numerous theories on the cause of cancer.  With 
the 19th century contributing anesthesia and the use of X-rays and the 20th 
century providing the discovery of the actual composition and structure of DNA, 
cancer can no longer be presumed as incurable, with numerous treatments 
available including radiation therapy, chemotherapy, and hormone therapy 
discussed below [39]. 
 Current Treatments.  Radiation therapy has been used since its 
development in the 19th century as a local therapy against cancerous areas of 
the body.  Using high energy rays to damage DNA, reproducing cancer cells are 
killed due to the high frequency of their replication.  Although induced DNA 
damage also targets normal cells, they are able to repair DNA damage due to the 
much slower growing cycle than that of cancer cells.  Major side effects are 
related to the area of exposure including skin reactions, hair loss, fatigue, and 
nutritional problems, but gradually lessen after treatment is complete.  Radiation 
treatment is normally used in combination with other types of cancer treatments 
[35]. 
 Perhaps the most common method of cancer treatment, chemotherapy 
uses alkylating agents or other toxins to destroy rapidly dividing cancer cells in 
the body by destroying their DNA.  Known as systemic therapy, these agents are 
able to travel and target cancer throughout the body after administration either 
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orally, intravenously, directly in a targeted body cavity, or intra-arterially.  Since 
these toxins are unable to distinguish between cancerous and healthy cells, side 
effects commonly occur in other normal body cells that proliferate frequently such 
as in the hair, skin, and digestive tract [38]. 
 After it was observed that removal of the ovaries severely decreased the 
onset of breast cancer in women, hormone therapy became widespread 
treatment for cancers such as breast and prostate cancer, which are highly 
dependent on the amount of estrogen and testosterone in the body, respectively 
[39].  This therapy blocks hormones from acting on cells, prevents the host from 
producing the hormone, or eliminates the receptors for the hormone on the host 
cell.  Because the effects are widespread, this treatment is also considered 
systemic with drawbacks mainly caused by the lack of hormone in the body.  
Women under estrogen therapy experience menopause symptoms while men 
under testosterone therapy experience hot flashes, nausea, a loss of sex drive, 
and in severe cases, impotence [36].   
 Perhaps the most modern treatment after the development of molecular 
biology in the 20th century, gene therapy targets the mutations in the host genes 
that contribute to the development of cancer.  Targets for this therapy vary as 
some replace missing or malfunctioning genes, such as the “tumor suppressor 
gene,” while others hope to use the host immune system to trigger an attack on a 
gene inserted into the body.  To efficiently transport these genes, vectors must 
be used, such as deactivated viruses unable to replicate within the host.  The 
most common side effect of such therapy is the body’s rejection to this foreign 
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vector-gene system causing possible fever, decrease in blood pressure, 
vomiting, and headache [37].  It is this type of therapy that the remainder of this 
paper focuses on, combining the prostate specific antigen (PSA) gene with a 
deactivated adenovirus and other polymer vectors in hopes of mounting an 
immune attack against prostate cancer.  
 Prostate Cancer.  Cancer is defined as a malignant, invasive growth 
caused by abnormal cell division, most likely occurring after excision of a primary 
tumor and traveling (metastasizing) to other sites in the body [5].  In the United 
States, prostate cancer is the most common cancer and the second deadliest 
cancer among men.  The American Cancer Society predicts that in 2008, 
186,320 men will be diagnosed and, of those diagnosed cases, 26,660 will prove 
lethal [2].  While the average age of patients suffering from prostate cancer 
between 1973 and 1987 was 67 years old, the incident of the disease increases 
drastically at approximately 50 years of age, with 1 in every 4 men showing 
symptoms of prostate cancer [3].  While no known causes have been identified, 
approximately 5-10% of cases are predicted to have a strong inherited 
component, with over 90% of all cancers observed to contain some type of 
genetic mutation [4, 5].  Ethnicity plays a minor role with twice as many African 
American males suffering from the disease compared to European-decent, and 
Asians, American Indians, and the Latino communities contributing the lowest 
incidence [4].  
 Disease Progression.  Prostate cancer progresses very slowly through 
various phases: prostatic intraepithelial, neoplasia (tumor growth), localized, 
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metastases, and finally to hormone refractory [5].  If diagnosed early with the 
cancer localized in the prostate, treatment options include: radical prostatectomy 
(removal of the prostate), external radiotherapy, brachytherapy (otherwise known 
as interstitial radiotherapy), and prolonged observation and surveillance of the 
disease progression.  While successful prostatectomy should result in 
undetectable prostate-specific antigen (PSA) levels after 3 weeks, 5 years post 
operation have shown rapid increase in PSA levels in 15-40% of all cases.  Of 
those patients diagnosed with advanced or metastasized prostate cancer, anti-
testosterone therapy and other hormone therapies remain the only option [8].  
Removal of the prostate is not suggested at this level of diagnosis due to the 
increased chance of metastasizing the cancer.  No other treatment options exist 
once a tumor becomes hormone refractory and no longer responds to hormone 
therapy [6] and once metastasized, the cancer is ultimately incurable due to 
uncontrollable tumor growth [7]. 
 Prostate-Specific Antigen (PSA).  Due to the lack of cancer treatment 
available once tumors become androgen-independent or metastasized, much 
research has been dedicated to the development of a novel immunotherapy, able 
to attack prostate cancer both localized to the prostate and throughout the body.  
As mentioned previously, prostate-specific antigen (PSA) is a single-chain 
glycoprotein secreted by both healthy and cancerous epithelial cells in the 
prostate gland [7].  Due to its delectability at low qualities in adult males, serum 
PSA is the most commonly used marker for prostate cancer malignancies, with 
research being conducted currently to induct a doubling-time test as a more 
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appropriate gage compared to the current static marker of PSA levels [9].  PSA 
expression increases from benign prostate epithelium tissue to cancerous tissue, 
with the intensity of PSA expression being directly proportional to the malignancy 
of the cancer [3, 8].  Yet, since the expression of PSA is limited to the prostate 
and since the organ, responsible for liquefying seminal clot after ejaculation, is 
nonessential for survival, PSA exists as the best candidate for targeted 
immunotherapy of prostate cancer [4, 8].  Unfortunately, the tissue-specific (not 
tumor-specific) self-antigen remains poorly immunogenic due to the host immune 
tolerance, with studies showing PSA-specific CD8+ T-cells exist in the body 
regardless of the presence of cancer [4]. 
 Immunotherapy.  The main challenge of prostate cancer immunotherapy 
is to override the host tolerance to PSA.  Gene therapy aims to introduce an 
effector gene (PSA) that can stimulate greater amounts of CD8+ T cells 
producing cytotoxic T lymphocytes (CTL) and interferon γ (IFNγ) activity to help 
control prostate cancer progression [5].  Prostate tumor cells have low 
antigenicity (ability to stimulate and interact with antibodies), which suggests that 
MHC class I tumor-associated antigen evasion is critical for the tumor growth.  
Since naked DNA is immediately degraded by the host immune response, the aid 
of gene delivery vectors and adjuvants are required to ultimately transfer 
recombinant PSA-DNA into human cells to achieve an anti-tumor, vaccinated 
effect.   
 Viral Gene Vectors.  Classified as viral or non-viral, the ideal vector must 
be highly specific to the target cell with efficient DNA delivery, remain nontoxic, 
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non-immunogenic, non-mutagenic, and for economic purposes be cheap and 
easily manipulated in vitro [10].  Due to their high efficiency of DNA transfer, viral 
vectors such as retroviruses, adenoviruses, vaccinia, and herpes simplex viruses 
are used in the majority of therapy research.  Adenoviruses offer many 
advantages such as their easy manipulation in vitro, the infection ability in both 
dividing and non-dividing cells, and the lack of DNA incorporation into the host 
genome, by-passing the previously mentioned concerns of mutagenicity.  
Adenoviruses also offer no viral proteins and therefore limit the viral immune 
response [8, 10].  With high affinity attachment to cell surfaces, adenoviruses can 
internalize and translocate into the nucleus with protein expression detectable 
within 6 hours post injection [11]. 
 Non-Viral Gene Vectors.  Non-viral gene vectors can be synthetic or 
natural vehicles for the protection and introduction of DNA into a target cell [11].  
Benefits include but are not excluded to: capacity to target specific receptors 
without undesired attachment, an unlimited DNA-cargo capacity, and the 
potential to minimize the host immune response.  Popular non-viral vectors 
include polycation complexes, whose positively charged backbone allows easy 
interaction and condensing of the gene, which can be transported to into the 
nucleus more efficiently.  The neutralization of the overall charge can help enable 
binding to specific target cells without interacting with host systemic clearance 
mechanisms, such as macrophages.  Disadvantages of non-viral vectors include 
high toxicity, poor storage stability in vivo, and much lower transfer efficiency 
than viral-based vectors.  Such vectors include polyethylenimine (PEI), chitosan, 
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and the coating of polymers with CD3 antibodies, each of which will be discussed 
in greater detail later in this report. 
 Ad5-PSA Vaccine.  In the late 1990’s, scientists at the University of Iowa 
developed a PSA-recombinant, replication-deficient viral vector, the Adenovirus5-
PSA (Ad-PSA), that generated strong PSA-specific anti-tumor immune 
responses in a prostate cancer mouse model [7, 16].  Directly proportional to the 
antigen-specific tumor destruction [5], CD8+ T cells were identified as the primary 
effector cells, capable of challenging subcutaneous injections of prostate cancer 
cells but unable to act on pre-existing mouse tumors [7, 14].  Phase I clinical 
trials, mainly responsible for determining the safety, dosage, and effectiveness of 
the vaccine, were a great success in patients with hormone refractory prostate 
cancer [5].  Research was further expanded in 2006 as the effective Ad-PSA was 
first combined with known adjuvant CpG-ODN to increase the tumor protection of 
prostate cancer.  With further support of the enhancement of CD8+ T cell 
cytotoxic T lymphocyte (CTL) activity of the PSA-bearing tumor cells, both in vitro 
and in vivo, this study stimulated further research into a hybrid vector of the 
adenovirus and a non-viral adjuvant [12].  In order to model the prostate cancer 
on transgenic mice, the recombinant type-5 adenovirus carrying the ovalbumin 
(Ad-OVA) gene was created [13].  Unfortunately, the major factor restricting the 
success of the adenovirus as a gene vector is the host neutralizing anti-
adenovirus antibodies, since most humans and animals have been exposed to 
the virus, mainly due to its collaboration with the common cold [15].  
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  To help increase the half-life of the viral vaccine by avoiding neutralizing 
host antibodies, it was proposed to coat the vaccine in polymers as protection 
[16].  Research on hybrid vectors consisting of PEI/DNA combinations further 
encompassed by the adenovirus vector have unfortunately been halted by the 
same host immune obstructions observed in viral vectors [11].  Therefore, the 
focus of this study was to observe the stimulation of OVA-specific CD8+ T cells 
using the Ad-OVA vaccine, coated with the three polymers listed previously: PEI, 
chitosan, and chitosan coated with CD3 antibodies (chito@CD3). 
 Barriers in Gene Delivery.  Known barriers to non-viral gene transfer 
include: i) surviving the extracellular matrix before targeting the cell, ii) delivery to 
the cytoplasm from the endosome, iii) transversing the cytoplasm to the nucleus, 
and iv) disassociation from the DNA for transcription [17, 22, 23].  Starting in the 
extracellular matrix, the positive charge of most non-viral vectors can accumulate 
and interact with non-specific targets such as red blood cells and other organs 
prior to target contact [23].  DNA must stay well protected and compacted from 
enzymes and DNA nucleases.  Upon contacting the targeted cell ligand, the 
polyplex must enter by endocytosis, a fete determined by size, hydrophobicity, 
polymer type, and surface charge [18], which progresses into a late state before 
fusion with acidic lysosomes and degradation.  Therefore, the vector must be 
able to escape the endosome to avoid further degradation after lysosome fusion.  
The vector must then transverse the cytoplasm to the nucleus and travel across 
the nuclear pore complex while disassociating from the contained gene [11, 17].  
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The following three polymers have been identified as potential non-viral vectors 
due to described characteristics overcoming some of the barriers listed above. 
 PEI.  Polyethylenimine (PEI) is a polycationic, synthetic polymer that has 
had success both in vivo and in vitro with gene delivery as a plasmid carrier [19].  
Due to the positive charge of the polymer, PEI is able to compact negatively-
charged DNA very tightly, allowing easy protection and transversion through the 
extracellular matrix and the cytoplasm.  Since the DNA phosphate backbone 
provides an overall negative charge, the PEI/DNA complex as a whole allows a 
nearly neutralized charge, avoiding attachment to red blood cells and untargeted 
organs extracellularly.  Due to the primary, secondary, and tertiary amine groups 
repeated throughout the PEI backbone, PEI acts as a pH buffer and allows lysis 
of the endosome by becoming a “proton sponge” [21, 22, 24].  At neutral pH, PEI 
captures protons moving into the endosome causing chloride ion influx, ultimately 
causing osmotic swelling, bursting, and escape from the endosome [22, 23].  
Therefore, the PEI/DNA complex is able to escape lysosome degradation and 
move through the nuclear pore complex with its tightly compacted carrier plasmid 
[19].  Unfortunately, high transfection at large molecular weight PEI corresponds 
to high toxicity due to adaptive immune responses to free polymers at high 
concentrations and is limited by low transfection efficiency compared to viral 
transfection, due to mitotic activity required for gene uptake [23, 25].  Linear PEI 
resulted in higher viability and transfection over branched PEI [21] and was 
therefore used in this experiment. 
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 Chitosan.  A natural cationic polysaccaride, chitosan is derived from 
chitin, found in the exoskeletons of crustaceans such as crawfish and insects [17, 
28], and became popular in pharmaceuticals due to its biocompatibility, non-
toxicity, and biodegradability confirmed in vivo in mice models [26, 27].  The high 
viscosity and positive charges form strong interactions with negatively-charged 
residues, and have been found to increase the half-time of antigen clearance, 
allowing more exposure in vivo [27].  Compared to PEI, chitosan contains limited 
buffering capacity but also minimal cytoxicity.  Instead of becoming a “proton 
sponge”, at physiological pH, chitosan becomes insoluble, ensuring that the 
chitosan/DNA complexes created at low pH remain physically stable without 
chemical crosslinking, and giving physical protection from nuclease attack [29].  
Chitosan has been applied to vaccines in a powder form with success facilitating 
immunization through nasal administration [18] and, in combination with a 
hydrogel, chitosan has enhanced tumor-specific CD8+ T cell immunity post 
vaccination [26].  Due to its high retention of antigen, chitosan has been labeled 
an ideal vaccination scenario targeting the sight of inflammation while generating 
an adaptive immune response [28].   
 CD3 Complex Antibodies.  The CD3 complex consists of glycoproteins 
linked to the antigen receptors exclusively on T lymphocytes [31, 33].  CD3 
antibodies have been used to activate peripheral T cell independent of antigen 
presentation [30].  Depending on the cell-line, the incorporation of a CD3 ligand 
has resulted in a 1,000 fold increase in transfection efficiency [23].  It has been 
demonstrated that CD4 T cells activated in vitro by CD3 antibodies were able to 
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generate antigen-specific memory CD4 T cells in antigen-free adoptive hosts, 
even after prolonged absence of antigen exposure [30].  INFγ was also produced 
in high quantities in adoptive hosts.  CD3 antibodies have also been found to 
stimulate effector CD4+ T cells to suppress both proliferation and cytokine 
production in target prostate cells [32].  In other studies, antiCD3 molecules have 
had success with initial activation through the cell cycle, but only in the presence 
of accessory cells [31].  Yet, other results indicate that CD3 antibodies do not 
initiate CTL lysis but rather inhibit target-cell recognition in the absence of Fc 
receptors; this indicates that the CD3 complex does not play a role in the initial 
killing of the target cell but acts in the CTL recognition of the antigen [34].  This 
study uses the antibodies to target the vaccine to the CD4 T cell to stimulate an 
adaptive immune response, along with the protection characteristics already 
listed for polymer chitosan. 
 Immune Cells Targeted.  Intracellular staining, tetramer staining, and 
cytotoxic T lymphocyte (CTL) assays were performed to quantify the immune 
response for each vaccine group.  In the intracellular staining, rat IgG2a-FITC 
labeled anti-mouse CD8a antibody was used to stain cells for the CD8 surface 
marker and rat IgG1-PE labeled anti-mouse IFNγ was used to stain for 
intracellular IFNγ expression [6], mainly to identify an inflammatory response to 
the vaccine.  MHC:peptide tetramer complexes are stained to identify that the 
response has been antigen-specific since tetramer complexes display a distinct 
epitope to the immune system.  Both sets of staining were analyzed using flow 
cytometry (FACS), which causes the dyed cellular receptors to excite and 
 14 
fluoresce as they pass through the laser light and are scattered [1].  CTL assays 
were used to identify the ability of the stimulated T lymphocytes to kill targeted 
cells producing PSA.  By injecting target cell lines, one producing PSA and a 
negative control, with Cromium-51 isotope and incubated with stimulated T cells, 
the amount of lysed target cells can be measured by the amount of radiation 
released using a gamma counter [1]. 
 
MATERIALS AND METHODS 
 Animals.  C57/BL/6 (H-2b) mice, approximately 6 to 8 weeks of age, were 
purchased from National Cancer Institute (Bethesda, MD).  All protocols were in 
accordance to regulations and recommendations by UIACCU.  The mice were 
maintained in filtered cages at the VA Animal Research Facility before and during 
use. 
 Vaccines and vaccination.  C57/CL/6 mice were injected with doses of 
adenovirus-OVA, adenovirus-LacZ (containing a gene encoding for β-
galactosidase), polyethylenimine, chitosan, chitosan coated with CD3 antibodies, 
the adenovirus-OVA combined with each of the above polymers, and the 
adenovirus-LacZ combined with each of the above polymers; eleven groups 
consisting of two mice per group were vaccinated.  The mice were injected with a 
dose of 108 pfu of the vaccine; Ad-OVA and Ad-LacZ were created in the method 
explained in Elzey et al. [7] and were obtained from the University of Iowa Gene 
Vector Core.  The adenovirus and polymer vaccine combination were prepared 
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by the pharmacology lab of Dr. Aliasger Salem and Dr. Zhang Xueqing at the 
University of Iowa.  Each combination was mixed prior to vaccination. 
 Spleen Harvest, Processing, Staining.  The spleens of mice were 
obtained from immunized mice 14 days post vaccination.  Two mice were 
sacrificed in order to obtain two spleens per group. 
 In order to the harvest the spleen, the mouse was sacrificed using carbon 
dioxide gassing.  Placed on its right side, the fur was wetted with ethyl alcohol 
and a 2 cm incision with scissors was made through the fur, with the fur pulled 
back using forceps.  Another small incision was made in the inner layer of the 
skin and the spleen was identified by the dark, elongated, flat characteristic of the 
organ located on the left side of the mouse.  The spleens from each group were 
placed in 5% FBS/PBS. 
 After the spleen was harvested, it was grinded used frosted slides into 
single-cell suspensions.  The suspensions were washed, centrifuged at 150 x g 
and suspended in 1 ml of ACK buffer for one minute, the latter for the lysis of 
contaminating red blood cells.  The cells were again washed and centrifuged with 
the cell suspensions ran through a cell strainer and again centrifuged.  The cells 
were resuspended in 10 ml of 5% FBS/PBS, counted, and 2 x 107 cells were 
placed into 96 well round-bottom plates and 24 well flat-bottom plates used for 
the intracellular staining and the cytotoxic T-lymphocyte assays, respectively.   
 The cells were centrifuged and were incubated for 15 minutes at 4 C with 
Fc-block to reduce the non-specific adherence of antibody molecules.  Following 
a wash the cells were respectively stained respectively with rat IgG2a-FITC 
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labeled anti-mouse CD8a for CD8 T-cells, PE-Cy5 for CD3 T-cells, and rat IgG1-
PE labeled anti-mouse IFNγ  for INFγ staining.  Each group contained 
unstimulated, SINFEKL (American Peptide Company; Tetramer antibody), and 
P/I (15 µL PMA/ 15 µL Iomycin/ 70 µL PBS; positive control group), all stained 
with the antibodies listed above. 
 The CTL assay plates were set up with 500 µL target cell line, 100 µL 
spleenocytes, 500 µL IL-2 (Grant; to allow lymphocytes to remain viable), and 
900 µL CTL media.  After 5 days incubation, Crominum-51 was added, the wells 
serially diluted, and the supernatants were evaluated using a COBRATM II, Auto-
gamma counter (Packard Instrument Company, IL). 
 For the tetramer assay, each group was stained with the PE-Cy5 and FitC 
antibodies listed above, incubated for 30 minutes with tetramer (Beckman 
Coulter), and then fixed with PFA.  After the above preparation, the ICS and 
tetramer plates were analyzed using FACS discussed above. 
 Antibodies.  All antibodies were purchased from eBiosciences and 
BioLegend. 
 Flow Cytometric Analysis.  Flow cytometric analysis was performed 
collecting 1 x 105 events and data were analyzed with Flow Jo 6.4 (Tree Star, 
Stanford) software. 
 
 
 
 
 17 
RESULTS 
 Expression of Antigen-Specific INFγ+CD8+ T-Cells.  In an effort to first 
understand how each vaccination group differed in their immunological response 
elicited by the respected adenovirus-OVA (Ad-OVA), adenovirus-LacZ (Ad-
LacZ), or in combination with polyethylenimine (PEI), chitosan, or chitosan 
coated with CD3- antibodies (chito@CD3), spleen lymphocytes (2 spleens per 
group) 14 days post vaccination were stained for OVA-specific IFNγ+ CD8+ T-
cell.  Interferon γ is a protein synthesized post-viral infection and so-named due 
to its interference in the viral reproduction.  Interferon γ is unique from interferons 
α and β, since it is not directly induced but produced later as a major contributor 
in the adaptive immune response to foreign pathogens [1]. 
INFg+CD8+ T-cells
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Figure 1. CD8+INFg+ T-cells activated by the vaccinated groups. 
Using flow cytometric analysis to identify the dual positive T-cells for each group, 
Figure 1 was generated to identify the overall trend of every vaccination group.  
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Using the SINFEKL as the OVA peptide-specific antibody, the number of 
stimulated T-cells was corrected by subtracting the unstimulated stained T-cells 
from each group to give an accurate depiction of the adaptive immune response.  
Using LacZ as a negative control to the OVA-induced immune response, the Ad-
OVA vaccine elicited a greater adaptive response compared to the LacZ.  It 
should also be noted that the PEI, chitosan, and anti-CD3 chitosan polymers 
individually produced no INFγ+CD8+ T-cell immune response compared to that 
generated by the negative control, suggesting no adjuvant effects.  Error bars of 
+25% were included in Figure 1 to compensate for the different in stimulated T 
cell values of the two spleen harvests and staining assays done in duplicate for 
this experiment.   
 To further analyze the selected hybrid vectors of Ad-OVA and polymer, 
Figure 2 includes only the OVA, LacZ, and the OVA combination with each 
polymer.   
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Figure 2. INFγ+CD8+ T-cells activated by each OVA-specific group. 
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From the graph, it can seen that Ad-OVA, OVA-Chitosan, and OVA-Chito@CD3 
all generated INFg+CD8+ immune responses, with OVA-chitosan contributing to 
more than double the amount of activated T-cells than the Ad-OVA vaccine 
alone.  Ad-OVA combined with PEI actually gave a diminished immune 
response, stimulating less T-cells than the Ad-LacZ vaccine and less than the 
unstimulated T-cells stained, as identified by the negative number above.  Since 
IFNγ induction is post-viral infection, it is probable that the synthetic PEI polymer 
was destroyed and filtered through the body before the adenovirus-OVA could be 
exposed to elicit the stained immune response.   
 It should be noted that due to ulcerations at the injection sites, the mice 
injected with the LacZ-chitosan combination were sacrificed early and could not 
be used for comparison in this report.  Therefore, a possible false positive of 
OVA-chitosan by contamination must be acknowledged as a possible cause of 
the stimulated immune response.  
 Expression of Antigen-Specific Tetramer+CD8+ T-Cells.  To compare 
the immediate immune response elicited by each vaccination group, spleens 
lymphocytes 14 days post-vaccination were stained for the OVA-specific MHC 
Class I Tetramer.   
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Figure 3. Tetramer+CD8+ T-cell activation for all vaccinated groups. 
Figure 3 shows similar immune response to the intracellular cytokine staining for 
INFγ above.  Since the assays were done in duplicate, error bars are provided at 
+25% to attribute to the discrepancies between trials.  Identical to the INFγ 
staining, OVA, OVA-Chitosan, and OVA-Chito@CD3 all stimulated OVA-specific 
tetramer positive responses, with each individual polymer group resulting in 
comparably low percentages, implying they are not immunogenic.  Although 
Figure 3 provides visual representation of the three groups providing the greatest 
stimulation, with the OVA-chitosan group providing only 0.5% higher positivity 
than the negative control, Ad-LacZ group, the immediate immune response after 
14 days vaccination gives comparably weak immunization for the OVA-specific 
antigen. 
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 Activation of OVA-specific peptide:MHC class I complex cytotoxic T-
cells.  To test the OVA-specific cytotoxicity, spleen lymphocytes 14 days post-
vaccination were serial diluted with two cells line: EL4, negative control cell line, 
and EL7, producing ovalbumin proteins.   
Cytotoxic T-Lymphoctye Assay - EL7 only
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Figure 4. Activation of OVA-specific peptide:MHC class I complex cytotoxic T-cells. 
 Figure 4 shows the progression of cell lysis as the effector cells (spleen 
lymphocytes) become denser compared to the target cell line (EL4 or EL7).  
Concentrating on the top three data series belonging, from top to bottom at 20 
E/T ratio, to OVA-Chitosan, OVA, and Ova-Chito@CD3, each series tended to 
peak between 50-60% lysis and began to plateau at 20 E/T ratio.  Figure 4 
recognizes that not only does the Ad-Ova vaccine and polymer combinations 
above elicit an adaptive immune response in vivo, they are able to directly lyse 
antigen-specific cells when combined in vitro. 
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 Yet, compared to assay trials non-specific to the scope of the report, a 
60% lysis is a weak CTL response in comparison to the +80% lysis resulting from 
previous experiments with the Ad-OVA vaccine.  This suggests that 14 day 
immunization may not allow enough proliferation of antigens-specific cytotoxic T 
lymphocytes.  It should be noted that the duplicate trial for this assay was 
contaminated during preparation and could not be used for comparison in this 
report. 
 
DISCUSSION 
 Administration with the Ad-OVA vaccine has shown to stimulate an 
immune response against ovalbumin in a mice model, yet the viral vaccine alone 
was not able to actively destroy antigen-specific prostate tissues without 
necessary accessory cells [13].  PEI has been proven to efficiently condense 
DNA and transfect into target cells, yet at lower transfection efficiency than the 
viral vectors [14].  PEI also has high toxicity directly related to high transfection 
efficiency [23, 25].  Chitosan, a natural polysaccharide, has been proven to also 
effectively deliver DNA to the target nucleus with lower toxicity and 
immunogenicity, but also lower effciency than the viral vectors [26, 27].  CD3 
antibodies have been used previously in conjuction with PEI to target the CD3 
complex unique to CD4 T cell, creating greater specificity and initiating 
proliferation into the cell cycle [23].  In this experiment, we investigated the 
possible adjuvant effects and short-term protection offered by each polymer 
complex to the vaccine-induced immune response using the Ad-OVA vaccine. 
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 The results of this experiment show that each polymer complex 
individually offers no adjuvant effects to the stimulated immune response offered 
by the vaccine.  Referring to Figures 1 and 3 above, the mice injection with only 
PEI, chitosan, and chito@CD3 did not stimulate the production of CD8+INFγ+ T 
cells or the antigen-specific tetramer complex compared to the negative control 
of the Ad-LacZ vaccination groups.  These results suggest that without the 
ovalbumin gene present in vivo, even in the presence of foreign microparticles, 
the immune system is not able to stimulate an antigen-specific immune 
response. 
 Yet, in combination with the Ad-OVA vaccine, chitosan and chito@CD3 
were able to both generate CD8+IFNγ+ T cell, CD8+Tet+, and cytotoxic T 
lymphocyte acitivity specific to the ovalbumin protein, while the combination of 
the vaccine with PEI actually diminished the immune response compared to the 
vaccine alone.  Referring to Figure 2 above, chitosan provided the most effective 
protection and transport for the Ad-OVA vaccine, followed by the chito@CD3 
complex.  Although the chito@CD3 was designed as a highly specified polymer 
with T cell ligand specificity, it is possible that the interaction between antibody 
and CD3 complex inhibited further recognition by the vaccine instead of 
stimulating proliferation, which is consistent with other research [34]. 
 Figure 3 mirrored the results found using intracellular staining, with 
chitosan and chito@CD3 both producing the stimulated of class I MHC:OVA-
specific tetramer complexes on CD8+ T cells.  Cytotoxicity was also activated by 
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the chitosan and chito@CD3 polymer combination with Figure 4 showing 50% 
target cell lysis at a 50:50 effector to target cell ratio. 
 The diminishment of immune response using PEI was mainly attributed to 
high toxicity and rapid clearance from the body.  Because PEI was interesting 
with a neutral-charged adenovirus rather than directly with the negatively-
charged DNA,  it is possible that the overall positive charge caused interaction 
with other organs and molecules extracellularly, causing the polymer, along with 
the Ad-OVA inside, to be cleared from the host before the DNA was able to be 
transfected and an immune response mounted.   
 
CONCLUSION 
 Although this experiment resulted in vaccine-induced immune responses 
to ovalbumin by combining the Ad-OVA vaccine with both chitosan and 
chito@CD3 polymers, it is unclear at what point in the transport from extracellular 
exposure to nuclear transcription the polymer aided in the transfection of the viral 
DNA.  Since the polymers themselves were proven to have no adjuvant effects 
independent of the vaccine, it could be suggested that their main aid comes in 
protecting the virus from the harsh environment and from mounted host-immune 
tolerance.  Since each vaccination group was sacrificed after 14 days, a time 
course study should be the next step in developing the effects of hybrid vector 
gene delivery systems.  By sacrificing two mice from each vaccination group 7, 
14, 21, and 28 days post vaccination, it will allow the assays to acknowledge 
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whether the polymer provides prolonged exposure and protection for the Ad-OVA 
vaccine or if another form of assistance was involved. 
 
FUTURE DIRECTION 
 Although the polymer-vaccine combinations did not produce an increased 
immune response, it is possible that such polymers may contribute extended 
protection to the vaccine from immune attack, allowing longer exposure of the 
vaccine and possibly increasing its success over time.  After the results of this 
experiment have been replicated and verified that the polymers indeed contain 
no adjuvant effects themselves, a time-course study should be pursued, 
sacrificing mice at staggering intervals such as 7, 14, and 21 days to observe 
how the induced immune response to PSA changes over time.  If the amount of 
activated T cells increases with time, it may be concluded that polymer-vaccine 
combinations are successful in sustaining the vaccine in the harsh environment 
inside the host and should be further pursued in clinical trials.  If such 
combinations of polymers and vaccines resulted in greater response to the Ad-
PSA vaccine, our generation may see the decline of chemotherapy toxins and 
radiation exposure and an increase in specific gene therapies effective as 
systemic treatments for metastatic cancers, without the side effects of host 
rejection. 
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